TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00578864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protracted Oral Etoposide
Description: Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Bolus Etoposide
Description: Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cycle 1, 2, and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 1, 2, and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cycle 3 and 5 with doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 3 and 5 with doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Standard weight-based dosing with cyclophosphamide
Study: NCT00961636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Description: Two 1g tablets ERN (2g total) once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ERN/LRPT
Description: One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
Study: NCT03658499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: two day skills group plus treatment adjuncts
Description: The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: two day skills group control group
Description: The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
Study: NCT00578864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Standard weight-based dosing with cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hematopoietic Factor
Description: Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Factor
Description: Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary tumor resection
Description: Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Description: Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
Study: NCT02531789

Intervention type: OTHER
Intervention: Observation
Description: C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
Study: NCT02280291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ankle SSB
Description: general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankle OnQ
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Study: NCT00788112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT03687281

Intervention type: OTHER
Intervention: Survey
Description: The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex.
Study: NCT03220438

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation
Study: NCT00799565

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: catch of blood
Description: 4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: catch of blood
Description: 4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects
Study: NCT02212860

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Then Surgery
Description: Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Then Surgery
Description: Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
Study: NCT01021800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS
Description: Cell infusion
Study: NCT02746809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreValve Evolut 34R TAVR system
Description: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)
Study: NCT01471184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Eye Drops/Nasal Spray
Study: NCT01352884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: Escalating doses of AMP-224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
Study: NCT00529048

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
Study: NCT03081988

Intervention type: OTHER
Intervention: chemoradiotherapy
Description: concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.

Intervention type: OTHER
Intervention: chemoradiotherapy
Description: concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
Study: NCT02280291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR SSB
Description: general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR OnQ
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Study: NCT03796091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Project Traditional
Description: Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Project Expanded
Description: Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
Study: NCT02514928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy
Description: Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pancreatoduodenectomy
Description: Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study: NCT02640846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Study: NCT02509598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vital Blue Dye (optional)
Description: A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
Study: NCT03623139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional education
Description: Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting
Description: The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
Study: NCT02147704

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet
Study: NCT04153006

Intervention type: DEVICE
Intervention: POC troponin analysis.
Description: Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
Study: NCT03209180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CarVeDilol-SR (Slow Release)
Description: patients will receive slow-release carvedilol (SR) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR (Immediate Release)
Description: patients will receive immediate release carvedilol (IR) twice daily
Study: NCT03051334

Intervention type: OTHER
Intervention: diagnosed as bicuspid aortic valve
Study: NCT05219422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ALERT
Description: 14 session drug prevention program for 7th and 8th grade youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ALERT
Description: 14 session drug prevention program for 7th and 8th grade youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Getting to Outcomes
Description: The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
Study: NCT02406547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
Study: NCT03323918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImPACT
Description: Teaching parents to train social communicative skills as outlined in arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
Study: NCT00649649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril Hydrochloride Tablets 40 mg
Description: 40mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accupril® Tablets 40 mg
Description: 40mg, single dose fed
Study: NCT03161392

Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up
Description: Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-guided percutaneous biopsy
Description: Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed.
Study: NCT01606995

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
Study: NCT01514734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol maleate fixed combination
Description: Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
Study: NCT01768676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01523249

Intervention type: DEVICE
Intervention: Lumbar 3D ultrasound scanning and palpation (Ultrasonix )
Description: Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
Study: NCT04158999

Intervention type: DEVICE
Intervention: milk analyzer
Description: Human Milk Sample

Intervention type: BEHAVIORAL
Intervention: Mother's nutrition values
Description: evaluation of nutritional elements of maternal onset with Bebis Program
Study: NCT00770978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole q12h
Description: Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole q8h
Description: Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
Study: NCT01396291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: asenapine-matched placebo, sublingual tablets, BID
Study: NCT03488056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICCMS
Description: The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SESC standard care
Description: Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
Study: NCT02168335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OrasaltsTM
Description: OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sea salt
Description: Unmedicated sea salt
Study: NCT00939991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostst/Bevacizumab/Temozolomide
Description: Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
Study: NCT01838824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
Study: NCT02563769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine
Description: 20/40mg Cocaine will be administered by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose